Recurrent ovarian cancer: maintenance olaparib effective in real-world setting

  • Cecere SC
  • Gynecol Oncol
  • 4 Nov 2019

  • curated by Deepa Koli
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Maintenance olaparib is effective and well tolerated in a real-world setting in BRCA-positive patients with recurrent platinum-sensitive ovarian cancer.
  • Patients with complete response after the last platinum therapy or normal Ca125 at baseline have longer PFS.

Why this matters

  • Postprogression data suggest cross resistance with chemotherapy and need further evaluation.

Study design

  • 234 consecutive BRCA-mutated patients with recurrent platinum-sensitive ovarian cancer (median age, 53.2 years) treated with olaparib between 2015 and 2019.
  • Funding: None disclosed.

Key results

  • Patients received ≥2 previous lines of platinum treatment.
  • Median follow-up, 15.5 months.
  • Median duration of treatment, 8.5 months.
  • Overall response rate (ORR), 46.3%.
  • Median PFS, 14.7 (95% CI, 12.60-18.03) months.
  • PFS was statistically longer in patients with normal serum Ca125 at baseline (Ca125, ≤35 vs >35 UI/mL; 25.5 vs 7.9 months; HR, 2.5; P=.001).
  • Patients who achieved complete response after last platinum-based therapy showed a statistically significant longer PFS vs those who achieved partial response (HR, 3.0; P=.001) or stable disease (HR, 2.7; P=.017).
  • Most common grade 3-4 toxicity: anemia (6%).
  • Of 66 evaluable patients who progressed and received further treatment, ORR was 22.2%, 11.1%, and 9.5% in patients with a platinum-free interval of >12, 6-12, and

Limitations

  • Retrospective analysis.

Please confirm your acceptance

To gain full access to GPnotebook please confirm:

By submitting here you confirm that you have accepted Terms of Use and Privacy Policy of GPnotebook.

Submit